– USA, MA – Seven Bridges, the biomedical data analysis company, today announced an expansion of its executive leadership team, including the appointment of Brandi Davis-Dusenbery, Ph.D., to the position of CEO. Formerly Seven Bridges’ Senior Vice President of Science & Product, Brandi succeeds co-founder Deniz Kural, Ph.D., who is today assuming the role of Executive Chairman of the Board of Directors.
“Brandi is the perfect person to lead Seven Bridges through our next phase of innovation and growth,” said Deniz Kural, executive chairman of the board of directors at Seven Bridges. “She has both the deep science background and operational experience to drive our mission of bringing the Seven Bridges Platform to commercial R&D enterprises and ambitious precision medicine projects around the globe.”
“I came to Seven Bridges in order to help develop new science and technology to improve health care around the world,” said Davis-Dusenbery. “I’m privileged to accelerate this work with our expanded leadership team, which shares a vision for making precision medicine a reality for research organizations worldwide.”
About Brandi Davis-Dusenbery, Ph.D.
As CEO, Brandi will focus on delivering continued product innovation and driving Seven Bridges’ global growth. In her prior role at the company, she was responsible for leading overall product strategy, managing product teams, and overseeing the company’s scientific projects, which span initiatives involving government, academia, and the private sector. Most notably, she guided the creation of the Cancer Genomics Cloud (CGC), an NCI pilot that now supports the analytic needs of about 1,500 researchers investigating petabytes of genomic data collected in The Cancer Genome Atlas (TCGA). The CGC’s success — for which it earned a 2016 Bio-IT Best of Show award — has prompted additional public and private research enterprises to choose the Seven Bridges Platform for their own large-scale projects. Brandi also has led the productization efforts for Seven Bridges’ Graph Genome Suite, which includes usable and reproducible bioinformatics pipelines for advanced population genomics.
In addition to her work with the Cancer Genomics Cloud and Graph Genome Suite, Brandi has been instrumental in Seven Bridges’ upward momentum, including securing strategic relationships with numerous commercial and government partners. Thanks to her leadership, Seven Bridges now powers projects for the Million Veteran Program, the Children’s Brain Tumor Tissue Consortium (CBTTC), and, most recently, the Cancer Moonshot’s Blood Profiling Atlas pilot, along with programs at multiple top-10 pharmaceutical companies.
Prior to Seven Bridges, Brandi worked as a Fellow at Harvard University’s Department of Stem Cell and Regenerative Biology, where she focused on applying next-generation sequencing technologies to understand changes that contribute to motor neuron loss in ALS. Her work has been published in Nature, Cell, Molecular Cell, and other leading journals.
“Brandi’s success with the Cancer Genomics Cloud, Blood Profiling Atlas, and other notable projects is proof positive that she knows what it takes to support analytics at a scale where breakthrough discoveries in precision medicine are more possible than ever before,” said James Sietstra, president of Seven Bridges. “She’s an exceptional choice to lead Seven Bridges at this time of rapid innovation and growth.”
About Seven Bridges
Seven Bridges is the biomedical data analysis company accelerating breakthroughs in genomics research for cancer, drug development and precision medicine. The scalable, cloud-based Seven Bridges Platform empowers rapid, collaborative analysis of millions of genomes in concert with other forms of biomedical data. Thousands of researchers in government, biotech, pharmaceutical and academic labs use Seven Bridges, including three of the largest genomics projects in the world: U.S. National Cancer Institute’s Cancer Genomics Cloud pilot, the Million Veteran Program, and Genomics England’s 100,000 Genomes Project. As the NIH’s only commercial Trusted Partner, Seven Bridges authenticates and authorizes access to one of the world’s largest cancer genomics dataset. Named one of the world’s smartest companies by MIT Technology Review, Seven Bridges has offices in Cambridge, Mass.; Belgrade; London; Istanbul; and San Francisco.
For more information : http://www.sevenbridges.com
- Disclaimer - News, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.
Comments are closed.